Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07499713 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Association of Serum VEGF-A and VCAM-1 Levels With Nailfold Capilleroscopic Alterations in Alopecia Areata

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 30, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Minor Study First Submitted
The goal of this observational study is to learn about microvascular changes and hair follicle activity in patients with alopecia areata. The main questions it aims to answer are: Do blood levels of markers related to blood vessel formation (VEGF-A) and inflammation (VCAM-1) differ between patients with alopecia areata and healthy individuals? Is there a link between these blood markers and structural changes in the nailfold capillaries? How do these markers relate to specific trichoscopic signs of disease activity (such as black dots or exclamation mark hairs) and the overall severity of hair loss (SALT score)? Researchers will compare patients with alopecia areata (grouped by disease duration: acute \<6 months vs. chronic \>6 months) to healthy volunteers to see if there is a significant difference in systemic and local vascular indicators. Participants will: Undergo a trichoscopic scalp examination to identify markers of disease activity (black dots, yellow dots, exclamation mark hairs) and calculate the SALT score. Have their nailfolds examined with a digital capillaroscope (50x) to detect microvascular alterations. Provide a blood sample to measure the levels of VEGF-A and VCAM-1.
Trial Details
NCT Number NCT07499713
Lead Sponsor Istanbul Training and Research Hospital
Conditions
(from sponsor)
Alopecia Areata, Alopecia Areata(AA), Alopecia Areata (AA)
Related terms Alopecia, Alopecia Areata
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov